<DOC>
	<DOCNO>NCT00532818</DOCNO>
	<brief_summary>The current standard recurrent , persistent metastatic cervical cancer palliative chemotherapy cisplatin topotecan , however , result need improve . Epigenetic aberration play important role cancer progression silence growth regulatory gene evidence inhibitor DNA methylation HDAC inhibition synergize cytotoxicity chemotherapy . Objective . To determine superiority epigenetic therapy hydralazine valproate plus standard cisplatin topotecan placebo plus cisplatin topotecan upon progression-free survival . Hypothesis . Hydralazine magnesium valproate associate cisplatin topotecan increase progression-free survival 4.6 7.6 month compare regimen chemotherapy plus placebo .</brief_summary>
	<brief_title>Hydralazine Valproate Cervical Cancer</brief_title>
	<detailed_description>Randomized , double-blind phase III trial . A total 143 patient ( alpha 0.5 , power 0.8 ) metastatic , persistent recurrent cervical cancer without previous systemic treatment randomize cisplatin topotecan + placebo cisplatin topotecan hydralazine valproate 6 course every 3 week . Patients receive oral dose hydralazine 182mg ( rapid ) 83mg ( slow ) accord acetylator phenotype single daily dose magnesium valproate oral dose 40mg/Kg t.i.d . Both drug slow-release formulation . Experimental drug placebo start seven day day 1 chemotherapy end sixth course .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<criteria>informed consent , histological diagnosis persistent , recurrent metastatic cervical carcinoma ; measurable disease physical examination , CT Scan , MRI PETCT . Biopsy require confirmation lesion unique , less 2cm long diameter clearly define border . Patients previous systemic treatment ( could receive chemotherapy radiosensitization pelvis paraaortic field . Aged &gt; 18 year , performance status 02 accord ECOG classification , adequate liver , hematological renal function , define : hemoglobin &gt; 10 g/L , leukocytes &gt; 4000/mm3 , platelet &gt; 100 000mm3 ; normal creatinine value creatinine clearance &gt; 60 mL/min ; total bilirubin &lt; 1.5 upper normal limit value . History allergy hydralazine valproate ; past present condition rheumatic disease , central nervous system disease , heart failure aortic stenosis postural hypotension diagnose physician ; newly diagnose hypertension patient without pharmacological treatment allow long treatment include hydralazine . Previous use experimental drug ( hydralazine magnesium valproate ) well patient pregnant breastfeeding . Other exclusion criterion uncontrolled systemic disease infection .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Epigenetic therapy</keyword>
	<keyword>Hydralazine</keyword>
	<keyword>Valproate</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Randomized</keyword>
	<keyword>Phase III</keyword>
</DOC>